Semin Cho, Eunjeong Kang, Ji Eun Kim, U Kang, Hee Gyung Kang, Minsu Park, Kwangsoo Kim, Dong Ki Kim, Kwon Wook Joo, Yon Su Kim, Hyung-Jin Yoon, Hajeong Lee
Cancer Res Treat. 2021;53(4):1015-1023. Published online January 18, 2021
Purpose
Acute kidney injury (AKI) in cancer patients is associated with increased morbidity and mortality. The incidence of AKI in lung cancer seems to be relatively higher compared with other solid organ malignancies, although its impact on patient outcomes remains unclear.
Materials and Methods
The patients newly diagnosed with lung cancer from 2004 to 2013 were enrolled in this retrospective cohort study. The patients were categorized according to the presence and severity of AKI. We compared all-cause mortality and long-term renal outcome according to AKI stage.
Results
A total of 3,202 patients were included in the final analysis. AKI occurred in 1,783 (55.7%) patients during the follow-up period, with the majority having mild AKI stage 1 (75.8%). During the follow-up of 2.6±2.2 years, total 1,251 patients (53.7%) were died and 5-year survival rate was 46.9%. We found that both AKI development and severity were independent risk factors for all-cause mortality in lung cancer patients, even after adjustment for lung cancer-specific variables including the stage or pathological type. In addition, patients suffered from more severe AKI tend to encounter de novo chronic kidney disease development, worsening kidney function, and end-stage kidney disease progression.
Conclusion
In this study, more than half of the lung cancer patients experienced AKI during their diagnosis and treatment period. Moreover, AKI occurrence and more advanced AKI were associated with a higher mortality risk and adverse kidney outcomes.
Citations
Citations to this article as recorded by
Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials Isabela Gonçalves Lima, Isabele Benck Usiro Cabral da Silva, Vitória Carpentieri Pípolo, Vinicius Daher Alvares Delfino, Paulo Roberto Bignardi Immunopharmacology and Immunotoxicology.2024; 46(4): 470. CrossRef
Prevalence of kidney disease in patients with different types of cancer or hematological malignancies: a cross-sectional study Feng Wu, Shiyuan Wang, Jialing Zhang, Peixin Wang, Aihua Zhang International Urology and Nephrology.2024; 56(12): 3835. CrossRef
Protective effect of reduced glutathione on acute kidney injury in lung cancer patients treated with cisplatin: a retrospective cohort study Ying Huang, Yang Li, Xialian Xu, Jie Teng, Xiaoqiang Ding, Jiarui Xu Renal Failure.2024;[Epub] CrossRef
Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis Huijuan Qian, Si Li, Ziyun Hu Oncology Letters.2024;[Epub] CrossRef
Association and prediction of red blood cell distribution width to albumin ratio in all-cause mortality of acute kidney injury in critically ill patients Chen Gao, Longkai Peng Frontiers in Medicine.2023;[Epub] CrossRef
Point of care ultrasonography in onco-nephrology: A stride toward better physical examination Bhavna Bhasin-Chhabra, Abhilash Koratala World Journal of Nephrology.2023; 12(2): 29. CrossRef
Protocolo diagnóstico y tratamiento de la nefropatía en los pacientes con neoplasia sólida Rodríguez Doyágüez, M.P. Morán Magro, C.M. Durán López, P. Martínez Miguel Medicine - Programa de Formación Médica Continuada Acreditado.2023; 13(82): 4870. CrossRef
von Hippel-Lindau (VHL) disease is an inherited syndrome manifesting with benign and malignant tumors. Deficiency of carnitine palmitoyltransferase type II (CPT2) is a disorder of lipid metabolism that, in the muscle form, manifests with recurrent attacks of myalgias often associated with myoglobinuria. Rhabdomyolytic episodes may be complicated by life-threatening events, including acute renal failure (ARF). We report on a male patient who was tested, at 10 years of age, for VHL disease because of family history of VHL. He was diagnosed with VHL but without VHL-related manifestation at the time of diagnosis. During childhood, the patient was hospitalized several times for diffuse muscular pain, muscle weakness, and dark urine. These recurrent attacks of rhabdomyolysis were never accompanied by ARF. The patient was found to be homozygous for the mutation p.S113L of the CPT2 gene. To the best of our knowledge, this is the first report of the coexistence of VHL disease and CPT2 deficiency in the same individual. Based on findings from animal models, the case illustrates that mutations in the VHL gene might protect against renal damage caused by CPT2 gene mutations.
Citations
Citations to this article as recorded by
A Deep Insight into Ferroptosis in Renal Disease: Facts and Perspectives Zhongyu Han, Yuanke Luo, Haoran Chen, Guochen Zhang, Luling You, Meiqi Zhang, Yumeng Lin, Lan Yuan, Shiyi Zhou Kidney Diseases.2024; 10(3): 224. CrossRef
Genotype–phenotype correlations and clinical outcomes of patients with von Hippel-Lindau disease with large deletions Kenan Zhang, Wuping Yang, Kaifang Ma, Jianhui Qiu, Lei Li, Yawei Xu, Zedan Zhang, Chaojian Yu, Jingcheng Zhou, Yanqing Gong, Lin Cai, Kan Gong Journal of Medical Genetics.2023; 60(5): 477. CrossRef
Idiopathic interstitial pneumonia in a patient with von Hippel–Lindau syndrome: a first case Letizia Corinna Morlacchi, Umberto Zanini, Andrea Gramegna, Paola Faverio, Francesco Blasi, Fabrizio Luppi ERJ Open Research.2023; 9(6): 00504-2023. CrossRef
The Cross‐Link between Ferroptosis and Kidney Diseases Jingyu Wang, Yi Liu, Yaqing Wang, Li Sun, Ana Cipak Gasparovic Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef
Prioritization of differentially expressed genes through integrating public expression data W. Xu, S. Li, Z. Zhang, J. Hu, Y. Zhao Animal Genetics.2019; 50(6): 726. CrossRef
Tumor lysis syndrome (TLS) has rarely been observed in solid tumors. We report on a case of a patient with advanced invasive thymoma who developed tumor lysis syndrome after chemotherapy. The potential complications of TLS should be considered in treatment of extensive thymoma.
Citations
Citations to this article as recorded by
Spontaneous tumour lysis syndrome as a rare presentation of thymoma with peripheral blood lymphocytosis Larry E Nyanti, Andy Sing Ong Tang, Adam Malik b Ismail, Lee Ping Chew, Tze Shin Leong Proceedings of Singapore Healthcare.2022;[Epub] CrossRef
Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases Riyadh M Alqurashi , Husam H Tamim, Ziyad D Alsubhi, Alyazid A Alzahrani, Emad Tashkandi Cureus.2022;[Epub] CrossRef
Spontaneous tumour lysis syndrome in cervical cancer Yu Kyung Kim, Ji Yeon Ham, Won-Kil Lee, Kyung Eun Song Journal of Obstetrics and Gynaecology.2017; 37(5): 679. CrossRef
Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature Aibek E. Mirrakhimov, Alaa M. Ali, Maliha Khan, Aram Barbaryan Rare Tumors.2014; 6(2): 68. CrossRef